Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry: Supply and Demand, Markets and Prices 2021-2027

Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status and Forecast (2016-2027)
      • 1.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Supply by Company

    • 2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Company
    • 2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Company
    • 2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Company
    • 2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Category

    • 3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Category Introduction
      • 3.1.1 Eluxadoline
      • 3.1.2 Alosetron
      • 3.1.3 Rifaximin
      • 3.1.4 Loperamide
      • 3.1.5 Diphenoxylate + Atropine
      • 3.1.6 Dicyclomine and Hyoscyamine
    • 3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Category
      • 3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Category (2016-2021)
      • 3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Category (2016-2021)
      • 3.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by End User/Segment

    • 4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by End User/Segment
      • 4.1.1 Hospitals
      • 4.1.2 Clinics
      • 4.1.3 Others
    • 4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by End User/Segment
      • 4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Region

    • 5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Region
      • 5.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Region
      • 5.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Region
    • 5.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status
    • 5.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status
    • 5.4 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status
    • 5.5 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status
    • 5.6 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status

    6 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status

    • 6.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Country
      • 6.1.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2016-2021)
      • 6.1.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status

    • 7.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Country
      • 7.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status

    • 8.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Country
      • 8.1.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status

    • 9.1 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Country
      • 9.1.1 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status

    • 10.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Country
      • 10.1.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Cost Analysis
    • 11.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channel and Distributors Analysis
      • 11.5.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channel
      • 11.5.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
    • 11.6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Downstream Major Buyers

    12 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Category and by End User/Segment

    • 12.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Category
      • 12.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Forecast by Category
      • 12.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Forecast by Category
      • 12.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast by Category
    • 12.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by End User/Segment
      • 12.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Forecast by End User/Segment
      • 12.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast by End User/Segment

    13 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Region/Country

    • 13.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Region (2022-2027)
      • 13.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Salix Pharmaceuticals Ltd
      • 14.1.1 Company Information
      • 14.1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
      • 14.1.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Pfizer
      • 14.2.1 Company Information
      • 14.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
      • 14.2.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 GlaxoSmithKline
      • 14.3.1 Company Information
      • 14.3.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
      • 14.3.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 AstraZenenca
      • 14.4.1 Company Information
      • 14.4.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
      • 14.4.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Astellas Pharmaceuticals
      • 14.5.1 Company Information
      • 14.5.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
      • 14.5.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Actavis
      • 14.6.1 Company Information
      • 14.6.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
      • 14.6.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis

    ...

      15 Conclusion

        16 Methodology

        Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

        Segmented by Category
        Eluxadoline
        Alosetron
        Rifaximin
        Loperamide
        Diphenoxylate + Atropine
        Dicyclomine and Hyoscyamine

        Segmented by End User/Segment
        Hospitals
        Clinics
        Others

        Segmented by Country
        North America
        United States
        Canada
        Mexico
        Europe
        Germany
        France
        UK
        Italy
        Russia
        Spain
        Asia Pacific
        China
        Japan
        Korea
        Southeast Asia
        India
        Australasia
        Central & South America
        Brazil
        Argentina
        Colombia
        Middle East & Africa
        Iran
        Israel
        Turkey
        South Africa
        Saudi Arabia

        Key manufacturers included in this survey
        Salix Pharmaceuticals Ltd
        Pfizer
        GlaxoSmithKline
        AstraZenenca
        Astellas Pharmaceuticals
        Actavis

        Buy now